Updated Jul 16, 2026
Talasaz AmirAli has filed 4 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $72.49M.
Amirali Talasaz is the Co-Chief Executive Officer and a Director at Guardant Health, Inc., a company specializing in liquid biopsy tests for cancer treatment. He has played a significant role in advancing the company's innovative diagnostic technologies.
| Role | Co-Chief Executive Officer, Director |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-02 | GH | Guardant Health, Inc. | F — Tax withholding / forfeiture | 17.1K | $170.77 | $2.92M |
| 2026-07-02 | GH | Guardant Health, Inc. | M — Option exercise | 9.7K | $0.00 | |
| 2026-07-02 | GH | Guardant Health, Inc. | M — Option exercise | 24.0K | $0.00 | |
| 2026-07-02 | GH | Guardant Health, Inc. | F — Tax withholding / forfeiture | 1.4K | $150.03 | $214K |
| 2026-07-02 | GH | Guardant Health, Inc. | M — Option exercise | 2.8K | $0.00 | |
| 2026-06-30 | GH | Guardant Health, Inc. | S — Open-market sale | 40 | $153.00 | $6K |
| 2026-06-30 | GH | Guardant Health, Inc. | S — Open-market sale | 46.7K | $152.20 | $7.10M |
| 2026-06-30 | GH | Guardant Health, Inc. | S — Open-market sale | 70.5K | $151.47 | $10.68M |
| 2026-06-30 | GH | Guardant Health, Inc. | S — Open-market sale | 25.8K | $150.53 | $3.89M |
| 2026-06-30 | GH | Guardant Health, Inc. | M — Option exercise | 143.0K | $4.18 | $598K |
| 2026-06-30 | GH | Guardant Health, Inc. | S — Open-market sale | 52.9K | $151.16 | $8.00M |
| 2026-06-30 | GH | Guardant Health, Inc. | S — Open-market sale | 64.0K | $150.49 | $9.64M |
| 2026-06-30 | GH | Guardant Health, Inc. | M — Option exercise | 111.8K | $4.18 | $467K |
| 2026-05-22 | GH | Guardant Health, Inc. | S — Open-market sale | 26.4K | $112.76 | $2.97M |
| 2026-05-22 | GH | Guardant Health, Inc. | S — Open-market sale | 37.9K | $112.02 | $4.25M |
| 2026-05-22 | GH | Guardant Health, Inc. | S — Open-market sale | 37.2K | $111.14 | $4.13M |
| 2026-05-22 | GH | Guardant Health, Inc. | S — Open-market sale | 28.9K | $110.10 | $3.18M |
| 2026-05-22 | GH | Guardant Health, Inc. | S — Open-market sale | 9.9K | $108.97 | $1.07M |
| 2026-05-22 | GH | Guardant Health, Inc. | S — Open-market sale | 33.1K | $108.11 | $3.57M |
| 2026-05-22 | GH | Guardant Health, Inc. | S — Open-market sale | 21.2K | $106.99 | $2.27M |
Amirali Talasaz is the Co-Chief Executive Officer and a Director at Guardant Health, Inc., a company specializing in liquid biopsy tests for cancer treatment. He has played a significant role in advancing the company's innovative diagnostic technologies.…
4 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 21 open-market sales ($72.49M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Talasaz AmirAli profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.